2023 / 04

Next Paper
DOI: 10.24075/brsmu.2023.031

CLINICAL CASE

Multidisciplinary approach to treatment of a patient with unresectable metastatic liver lesion spawned by HER2+ gastric adenocarcinoma giving

Kolomiets KV, Isaev IV, Kovalev VV, Grishchenko NV, Kokovihina DI, Morozova AA, Torosyan AR, Shashkova VV, Snegireva PV
About authors

Rostov State Medical University of the Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

Correspondence should be addressed: Karina V. Kolomiets
Krasnoarmeyskaya, 198, Novocherkassk, 346400, Russia; ur.liam@99_steimolok_anirak

About paper

Author contribution: Kolomiets KV — article authoring, editing; Isaev IV, Snegireva PV — article authoring, literature review, data analysis; Kovalev VV, Grishchenko NV — article authoring, literature review, data collection; Kokovikhina DI, Morozova AA — article authoring, literature review, study concept and design; Torosyan AR, Shashkova VV — article authoring, literature review, article revision.

Compliance with ethical standards: the patient has signed a voluntary informed consent to publication of anonymized medical information.

Received: 2023-06-27 Accepted: 2023-08-12 Published online: 2023-08-29
|
  1. Panda SK, Sahoo PK, Agarwala SK, Houghton TT, Chandrapattan PP, Sankar KV, Nag R. Evolution of treatment in gastric cancer- a systematic review. J Egypt Natl Canc Inst. 2022; 34 (1); DOI: 10.1186/s43046-022-00114-7.
  2. Malihova OA, Ryabova VE, Lozovaya VV, i dr. Rannij rak zheludka: klinicheskoe nablyudenie. RMZh. Medicinskoe obozrenie. 2022; 6 (6): 334–40; DOI: 10.32364/2587-6821-2022-6-6-334-340. Russian.
  3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68 (6): 394–424.
  4. Rykov OV, Parshin DV, Cxovrebov AT, Mirzoyan OS, Fyodorov DN, Tarasova IA, i dr. Rezul'taty lecheniya raka zheludka i metaxromnyh metastazov v pecheni i legkih. Hirurgiya. Zhurnal imeni N. I. Pirogova. 2017; (6): 69–71. Russian.
  5. Kuhlmann JB, Euringer W, Spangenberg HC, Breidert M, Blum HE, Harder J, et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol. 2012; 24 (4): 437– 43; DOI: 10.1097/MEG.0b013e3283502241.
  6. Kawahara K, Makino H, Kametaka H, Hoshino I, Fukada T, Seike K, et al. Outcomes of surgical resection for gastric cancer liver metastases: a retrospective analysis. World J Surg Oncol. 2020; 18 (1), 41; DOI: 10.1186/s12957-020-01816-9.
  7. Patetta MA, Isaacson AJ, Stewart JK. Initial experience with HydroPearl microspheres for uterine artery embolization for the treatment of symptomatic uterine fibroids. CVIR Endovasc. 2021; 4 (1): 32; DOI: 10.1186/s42155-021-00223-9.
  8. Sakaue M, Sugimura K, Masuzawa T, et al. Long-term survival of HER2 positive gastric cancer patient with multiple liver metastases who obtained pathological complete response after systemic chemotherapy: A case report. Int J Surg Case Rep. 2022; 94: 107097; DOI: 10.1016/j.ijscr.2022.107097.
  9. Abramov ME, Mashhelueva AYu, Chichikov EI. Ehffektivnaya farmakot. 2010; 3 (22): 46–49. Russian.
  10. Safronenko AV, Gancgorn EV, Kolomiec KV. Ehffektivnost' transarterial'noj himioehmbolizacii s bevacizumabom pri nerezektabel'nom metastaticheskom kolorektal'nom rake pecheni. Ehksperimental'naya i klinicheskaya farmakologiya. 2021; 84 (10): 25–28; DOI: 10.30906/0869-2092-2021-84-1025-28. Russian.
  11. Hochenkov DA, Volkova MI, Timofeev IV, Olshanskaya AS, Hochenkova YuA, Solomko Eh. Sh., i dr. Ehkspressiya faktora rosta ehndoteliya sosudov i ego receptorov pervogo i vtorogo tipov v kletkah pervichnoĭ opuholi u bol'nyh rakom pochki. Sibirskiĭ onkologicheskiĭ zhurnal. 2021; 20 (4): 64–72. DOI: 10.21294/1814-4861-2021-20-4-64-72. Russian.
  12. Ciaffaglione V, Modica MN, Pittalà V, et al. Mutual prodrugs of 5-Fluorouracil: from a classic chemotherapeutic agent to novel potential anticancer drugs. Chem Med Chem. 2021; 16 (23): 3496–512; DOI: 10.1002/cmdc.202100473.
  13. Mizusawa J, Morizane C, Okusaka T, Katayama H, Ishii H, Fukuda H, et al. Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group. Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT). Jpn J Clin Oncol. 2016; 46 (4): 385–88; DOI: 10.1093/jjco/hyv213.
  14. Mosconi C, Calandri M, Javle M, Odisio BC. Interventional radiology approaches for intra-hepatic cholangiocarcinoma. Chin Clin Oncol. 2020; 9 (1); DOI: 10.21037/cco.2019.12.15.
  15. Rahnemai-Azar AA, Weisbrod AB, Dillhoff M, Schmidt C, Pawlik TM. Intrahepatic cholangiocarcinoma: current management and emerging therapies. Expert Rev Gastroenterol Hepatol. 2017; 11 (5): 439–49; DOI: 10.1080/17474124.2017.1309290.